Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report

INTRODUCTION: Pegcetacoplan is a targeted complement component 3 (C3) therapy approved for adults with paroxysmal nocturnal hemoglobinuria (PNH; US) or PNH plus anemia despite C5-targeted therapy for ≥ 3 months (EU). Patients with PNH receiving pegcetacoplan in the phase 3 PEGASUS trial who experien...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Vivek, Koprivnikar, Jamie, Drago, Kristen, Savage, Jessica, Bachelor, Allison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567944/
https://www.ncbi.nlm.nih.gov/pubmed/37707673
http://dx.doi.org/10.1007/s12325-023-02653-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567944/
https://www.ncbi.nlm.nih.gov/pubmed/37707673
http://dx.doi.org/10.1007/s12325-023-02653-4

Ejemplares similares